title: Pleiotrophin modulates morphine withdrawal but has no effects on morphine-conditioned place preference.
abstract: Pleiotrophin (PTN) is a neurotrophic factor with important functions in addiction and neurodegenerative disorders. Morphine administration induces an increase in the expression of PTN and Midkine (MK), the only other member of this family of cytokines, in brain areas related with the addictive effects of drug of abuse, like the Ventral Tegmental Area or the hippocampus. In spite of previous studies showing that PTN modulates amphetamine and ethanol rewarding effects, and that PTN is involved in morphine-induced analgesia, it was still unknown if the rewarding effects of morphine may be regulated by endogenous PTN. Thus, we aim to study the role of PTN in the reward and physical dependence induced by morphine. We used the Conditioned Place Preference (CPP) paradigm in PTN genetically deficient (PTN-/-) and wild type (WT) mice to assess the rewarding effects of morphine in absence of endogenous PTN. Second, to study if PTN may be involved in morphine physical dependence, naloxone-precipitated withdrawal syndrome was induced in PTN-/- and WT morphine dependent mice. Although the increase in the time spent in the morphine-paired compartment after conditioning tended to be more pronounced in PTN-/- mice, statistical significance was not achieved. The data suggest that PTN does not exert an important role in morphine reward. However, our results clearly indicate that PTN-/- mice develop a more severe withdrawal syndrome than WT mice, characterized as a significant increase in the time standing and in the total incidences of forepaw licking, forepaw tremors, wet dog shake and writhing. The data presented here suggest that PTN is a novel genetic factor that plays a role in morphine withdrawal syndrome.
authors.affiliation: Pharmacology Lab, Department of Pharmaceutical and Health Sciences, Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain. Electronic address: esther.gramagecaro@ceu.es.
authors.forename: Esther
authors.initials: E
authors.lastname: Gramage
authors.affiliation: Pharmacology Lab, Department of Pharmaceutical and Health Sciences, Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Vicente-Rodríguez
authors.affiliation: Pharmacology Lab, Department of Pharmaceutical and Health Sciences, Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Herradón
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D003214:Conditioning, Classical / Q000187:drug effects*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D018345:Mice, Knockout; D009020:Morphine / Q000009:adverse effects* / Q000494:pharmacology; D009021:Morphine Dependence / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology; D009270:Naloxone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D012201:Reward; D013375:Substance Withdrawal Syndrome / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology
chemical_list: D002352:Carrier Proteins; D016207:Cytokines; D009292:Narcotic Antagonists; C066845:pleiotrophin; D009270:Naloxone; D009020:Morphine
keywords: Addiction; Dependence; Midkine; Morphine; Naloxone; Withdrawal